Henrich TJ, Schreiner C, Cameron C, et al. - Given the previous work reporting association of pharmacologic inhibition of the mammalian target of rapamycin (mTOR) with lower HIV‐1 DNA burden in the setting of renal transplantation, and in vitro studies suggesting the possibility of HIV transcriptional silencing in correlation with mTOR inhibition, researchers performed an open label, single‐arm study examining how the broad mTOR inhibitor, everolimus, affects residual HIV burden, transcriptional gene expression profiles, and immune responses in HIV‐infected adult solid organ transplant (SOT) recipients on antiretroviral therapy (ART). Although no overall effect of everolimus therapy on cell‐associated HIV‐1 DNA and RNA levels was noted in the entire cohort, there were significantly lower RNA levels among participants who maintained everolimus time‐averaged trough levels > 5 ng/mL during the first two months of therapy; this effect remained up to 6 months after the cessation of study drug. Significant correlation was observed of time‐averaged everolimus trough levels with greater inhibition of mTOR gene pathway transcriptional activity. In addition, treatment with everolimus resulted in reduced PD‐1 expression on certain T cell subsets.